Translating Evidence into Practice

DAY 1  (Saturday, 14th March 2020)

08:00 - 08:20
Opening Address
REBECCA DENT, Singapore / SHAHEENAH DAWOOD, UAE

08:20 - 09:20
Breakfast Satellite Symposium Sponsored by Roche
Multi-disciplinary perspectives on optimizing patient outcomes in HER2-Positive and triple-negative breast cancer
Chairperson: KHOO KEI SIONG, Singapore
Panel: HENRY CAIN, UK / HOPE RUGO, USA / TBA

PLENARY SESSION 1: Translational Breast Cancer Done Right!
Chairpersons: BENITA TAN, Singapore / TAM WAI LEONG, Singapore

09:20 - 09:40
Applying 2019 Breast Cancer Results into Clinical Practice
LISA CAREY, USA

09:40 - 10:00
Making new technologies relevant to clinicians in 2020
CHARLES PEROU, USA

10:00 - 10:20
Coffee Break and Poster Viewing

SESSION 2: Controversies
Chairpersons: KILEY LOH, Singapore / CHANG CHING WAN, Singapore

10:20 - 10:40
Debate - Should all ER-pos patients receive 10 years of endocrine therapy?
YES: ELAINE LIM, Singapore / NO: ERIC WINER, USA

10:40 - 10:55
Do all women < 40 require ovarian suppression?
LEE SOO CHIN, Singapore

10:55 - 11:10
Is there a role for SLN biopsy after neoadjuvant therapy?
HENRY CAIN, UK

11:10 - 11:30
Q and A

SESSION 3: Early Breast Cancer
Chairperson: WONG FUH YONG, Singapore

11:30 - 11:50
Optimizing adjuvant radiation therapy in breast cancer
PHILIP POORTMANS, France

11:50 - 12:50
Young Women Early Breast Cancer Rapid Fire Tumor Board
Chairpersons: SHAHEENAH DAWOOD, UAE / VERONIQUE TAN, Singapore
Panel: ERIC WINER, USA / JANICE TSANG, Hong Kong / LISA CAREY, USA / PHILIP POORTMANS, France
SUNG-DAE KIM, South Korea / YAP YOON SIM, Singapore

13:00 - 14:00
Lunch Symposium Sponsored by AstraZeneca

13:00 - 13:30
Optimizing Endocrine Therapies in the era of CDK4/6i
ERIC WINER, USA

13:30 - 14:00
Case studies
Moderator: TBA
Panel: ERIC WINER, USA / TBA

SESSION 4: Neoadjuvant/Adjuvant Therapy
Chairpersons: KARMEN WONG, Singapore / YEN-SHEN LU, Taiwan

14:00 - 14:20
Rationale choices of HER-2 directed therapy in early breast cancer?
SHAHEENAH DAWOOD, UAE

14:20 - 14:40
What is standard systemic therapy in neoadjuvant therapy in TNBC?
SUDEEP GUPTA, India

14:40 - 15:00
Q and A

15:00 - 15:20
Coffee Break

SESSION 5: Global Tumor Board
Chairpersons: HOPE RUGO, USA / SAMUEL OW, Singapore

15:30 - 16:30
Panel: AVA KWONG, Hong Kong / AZRIF MOHAMMED, Malaysia / GIUSEPPE CURIGLIANO, Italy
MASAKAZU TOI, Japan / PHILIP POORTMANS, France / SUDEEP GUPTA, India
THITIYA SIRISINHA DEJTHEVAPORN, Thailand / WONG NAN SOON, Singapore

16:30 - 17:30
Satellite Symposium Sponsored by Lilly
CDK4/6 inhibitors: Setting new standards for the management of HR+ HER2- Advanced Breast Cancer
Chairperson: YAP YOON SIM, Singapore
Panel: GIUSEPPE CURIGLIANO, Italy / TBA
08:00 - 09:00  Breakfast and Satellite Symposium Sponsored by Pfizer

LISA CAREY, USA / TBA

08:00 - 08:05  Introduction of the Session & Speaker

YOON SIN YAP, Singapore

08:05 - 08:30  Changing the trajectory of ER+ HER2- mBC: Clinical & Real World Outcomes

LISA CAREY, USA

08:30 - 08:45  Panel Discussion

Moderator: JANICE TSANG, Hong Kong
Panel: LISA CAREY, USA / NAPA PARINYANITIKUL, Thailand / BOMAN DHABHAR, India
MSTURA MD YUSOF, Malaysia / TBA

PLENARY SESSION 6: Interrogating the Immune system in Breast Cancer

Chairpersons: TEAH BIN TEAN, Singapore / PETER SCHMID, UK

09:00 - 09:20  Next generation technologies to discern sensitivity to immune checkpoint inhibition

CHARLES PEROU, USA

09:20 - 09:40  Debate - Should all TNBC metastatic breast cancer patients who are PD-L1 + receive immune checkpoint inhibitors?

YES: LISA CAREY, USA / NO: GIUSEPPE CURIGLIANO, Italy

09:40 - 10:00  Breast Cancer 2025 according to Eric

ERIC WINER, USA

10:00 - 10:20  Coffee Break and Poster Viewing

SESSION 7: Unique Clinical Scenarios in Metastatic Breast Cancer

Chairpersons: FAYE LIM, Singapore / VIROTE SRIURANPONG, Thailand

10:20 - 10:35  Novel Approaches to Oligometastatic Disease

PHILIP POORTMANS, France

10:35 - 10:50  Systemic Therapy in CNS metastases

YAP YOON SIM, Singapore

10:50 - 11:05  Unravelling the complexity of DNA Repair Strategies

TIRA TAN, Singapore

11:05 - 11:20  Access to care in the real world in Asia?

CHENG-HAR YIP, Malaysia

11:20 - 12:20  Molecular Tumor Board

Chairpersons: GIUSEPPE CURIGLIANO, Italy / SUDEEP GUPTA, India
Panel: PETER SCHMID, UK / SEOCK-AH IM, Korea / TIRA TAN, Singapore / SHAHEENAH DAWOOD, UAE
YEN-SHEN LU, Taiwan / JOLINE LIM, Singapore / SEE HUI TI, Singapore

12:45 - 13:45  Lunch Symposium Supported by MSD

12:45 - 12:50  Welcome and Introduction

TBA

12:50 - 13:30  Advances of Immunotherapy in Neoadjuvant TNBC (Triple Negative Breast Cancer)

Case studies sharing

PETER SCHMID, UK

13:30 - 13:45  Discussion: Q & A

Moderator: TBA
Panel: PETER SCHMID, UK / BENITA TAN, Singapore

SESSION 8: Novel Targets

Chairpersons: SUNG-BAE KIM, South Korea / MASTURA YUSOF, Malaysia

13:30 - 13:45  Novel Targets metastatic TNBC

PETER SCHMID, UK

13:45 - 14:00  Novel Targets HER-2 positive MBC

HOPE RUGO, USA

14:00 - 14:15  Novel Targets ER-positive MBC

SEOCK-AH IM, South Korea

14:15 - 14:30  Q and A

14:30 - 15:00  Coffee Break

15:00 - 16:30  “Official Best of SABCS® Review” 2019

Chairperson: WONG NAN SOON, Singapore
Panel: TBA

16:30 - 17:30  Satellite Symposium Sponsored by Novartis

“Novel Therapies in HR+ HER2- Advance Breast Cancer Treatment Landscape”
Chairperson: HOPE RUGO, USA
Speaker: GIUSEPPE CURIGLIANO, USA

apbcs.org